$150MSeries A, 18 February 2026
Emerges from stealth to advance KRSA-028, a shuttled anti-amyloid antibody, toward first-in-human studies by early 2027.
- Amount
- $150M
- Stage
- Series A
- Announced
- 18 February 2026
- Lead
- Wellington Management
- Other investors
- TCGX, Fairmount, Venrock, J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital
- Use of funds
- Emerges from stealth to advance KRSA-028, a shuttled anti-amyloid antibody, toward first-in-human studies by early 2027.
- Checked
- Announced by the company
- Source
- Korsana Biosciences emerges from stealth with $175M for Alzheimer's therapies businesswire.com